Aprea Therapeutics, Inc. (APRE)Healthcare | Biotechnology | Doylestown, United States | NasdaqCM
0.84 USD
-0.02
(-2.500%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.86 +0.02 (2.826%) ⇧ (Aug. 28, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:27 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish despite a recent bounce, as the stock trades at a significant discount to its moving averages and faces a critical regulatory deadline highlighted by recent news regarding an 180-day extension to meet a $1 bid. The recent price action shows a modest recovery from lows, but the underlying momentum remains fragile given the heavy volume and the fact that the price is still well below the 50-day average. Looking further ahead, the investment case is severely compromised by a catastrophic multi-year decline; the asset has lost nearly 99.7% of its value over the last five years, with every single year showing negative returns. This relentless downward trajectory suggests a fundamental business failure or a value trap where the market has permanently repriced the asset, rendering any current fundamentals irrelevant. Finally, there is no income component to consider, as the company has not paid a dividend in the last five years, offering no cushion for investors in this high-risk biotech sector. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.218828 |
| MSTL | 0.223753 |
| AutoETS | 0.227289 |
| AutoTheta | 0.294495 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 3.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.210 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 10,558,926 |
| Forward P/E | -2.89 |
| Beta | 1.59 |
| Website | https://aprea.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.45222932 |
| Address1 | 3,805 Old Easton Road |
| All Time High | 1,062.2 |
| All Time Low | 0.474 |
| Ask | 0.8594 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 913,470 |
| Average Daily Volume3 Month | 215,061 |
| Average Volume | 215,061 |
| Average Volume10Days | 913,470 |
| Beta | 1.588 |
| Bid | 0.7937 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 3.105 |
| City | Doylestown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8386 |
| Current Ratio | 13.554 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.9099 |
| Day Low | 0.8202 |
| Display Name | Aprea Therapeutics |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda | -13,201,041 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 2.269 |
| Enterprise To Revenue | -5,775.726 |
| Enterprise Value | -29,947,140 |
| Eps Current Year | -0.31333 |
| Eps Forward | -0.29 |
| Eps Trailing Twelve Months | -0.94 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.71202 |
| Fifty Day Average Change | 0.12658 |
| Fifty Day Average Change Percent | 0.1777759 |
| Fifty Two Week Change Percent | -45.22293 |
| Fifty Two Week High | 1.69 |
| Fifty Two Week High Change | -0.8514001 |
| Fifty Two Week High Change Percent | -0.50378704 |
| Fifty Two Week Low | 0.548 |
| Fifty Two Week Low Change | 0.2906 |
| Fifty Two Week Low Change Percent | 0.530292 |
| Fifty Two Week Range | 0.548 - 1.69 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,570,109,400,000 |
| Float Shares | 7,910,129 |
| Forward Eps | -0.29 |
| Forward P E | -2.891724 |
| Free Cashflow | -8,151,741 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | -0.0215 |
| Fullday Change Percent | -2.49971 |
| Fullday Price | 0.8623 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -6,715,780 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09174 |
| Held Percent Institutions | 0.18832001 |
| Implied Shares Outstanding | 12,591,136 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,676,246,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. |
| Long Name | Aprea Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 10,558,926 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_329831339 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -12,307,261 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,829,636 |
| Number Of Analyst Opinions | 4 |
| Open | 0.88 |
| Operating Cashflow | -12,168,011 |
| Operating Margins | -2,550.2551 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 215 948 4119 |
| Post Market Change | 0.023699999 |
| Post Market Change Percent | 2.8261387 |
| Post Market Price | 0.8623 |
| Post Market Time | 1,787,961,174 |
| Previous Close | 0.8601 |
| Price Eps Current Year | -2.6764114 |
| Price Hint | 4 |
| Price To Book | 0.2700805 |
| Price To Sales Trailing12 Months | 2,036.437 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.334 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.021499991 |
| Regular Market Change Percent | -2.4997084 |
| Regular Market Day High | 0.9099 |
| Regular Market Day Low | 0.8202 |
| Regular Market Day Range | 0.8202 - 0.9099 |
| Regular Market Open | 0.88 |
| Regular Market Previous Close | 0.8601 |
| Regular Market Price | 0.8386 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 343,096 |
| Return On Assets | -0.27733 |
| Return On Equity | -0.46147 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 12,591,136 |
| Shares Percent Shares Out | 0.0004 |
| Shares Short | 5,487 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 60,595 |
| Short Name | Aprea Therapeutics, Inc. |
| Short Percent Of Float | 0.0005 |
| Short Ratio | 0.11 |
| Source Interval | 15 |
| State | PA |
| Symbol | APRE |
| Target High Price | 5.0 |
| Target Low Price | 1.2 |
| Target Mean Price | 3.55 |
| Target Median Price | 4.0 |
| Total Cash | 41,233,428 |
| Total Cash Per Share | 3.275 |
| Total Debt | 0 |
| Total Revenue | 5,185 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.94 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.83138 |
| Two Hundred Day Average Change | 0.00721997 |
| Two Hundred Day Average Change Percent | 0.00868432 |
| Type Disp | Equity |
| Volume | 343,096 |
| Website | https://aprea.com |
| Zip | 18,902 |